Targets › ATXN2
2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Neurology; next expected readout Dec 2026.
Involved in EGFR trafficking, acting as negative regulator of endocytic EGFR internalization at the plasma membrane. (UniProt, Q99700)
Open in Phaseline: the race on ATXN2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Biogen | Diranersen Antisense oligonucleotide targeting ATXN2 mRNA | ATXN2 | Phase 2 | Mild Cognitive Impairment Due to Alzheimer's Disease | Jun 2028 |
| Arrowhead Pharmaceuticals | ARO-ATXN2 Injection Antisense oligonucleotide targeting ATXN2 mRNA | ATXN2 | Phase 1 | Spinocerebellar Ataxia Type 2 | Dec 2026 |
Spinocerebellar Ataxia Type 2 (1) Mild Cognitive Impairment Due to Alzheimer's Disease (1)
small molecule (1), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.